JEMPERLI 500 mg concentrate for solution for infusion
*Company:
GlaxoSmithKline (Ireland) LtdStatus:
No Recent UpdateLegal Category:
Product subject to medical prescription which may not be renewed (A)Active Ingredient(s):
This medicinal product is subject to additional monitoring.
*Additional information is available within the SPC or upon request to the company
Updated on 14 August 2024
File name
ie-pl-jemperli-issue8draft1-clean.pdf
Reasons for updating
- Change to section 4 - how to report a side effect
Updated on 04 July 2024
File name
ie-spc-jemperli-issue3draft1-Master.pdf
Reasons for updating
- Change to section 4.8 - Undesirable effects
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 04 July 2024
File name
ie&ukni-pl-jemperli-issue7draft1-Master.pdf
Reasons for updating
- Change to section 4 - possible side effects
Updated on 07 June 2024
File name
ie-spc-jemperli-issue2draft1-Master.pdf
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.8 - Undesirable effects
- Change to section 6.6 - Special precautions for disposal and other handling
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 07 June 2024
File name
ie&ukni-pl-jemperli-issue6draft1-Master.pdf
Reasons for updating
- Change to section 6 - date of revision
- Change to information for healthcare professionals
File name
Dostarlimab Patient Card_November 2023_Ireland.pdf
Reasons for updating
- Add New Doc
Updated on 26 February 2024
File name
ie-spc-Jemperli- issue1draft1-clean.pdf
Reasons for updating
- New SPC for new product
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 26 February 2024
File name
ukni-ie-PIL-Jemperli- issue5draft 1-clean.pdf
Reasons for updating
- New PIL for new product